3 Investor presentation First nine months of 2022 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), in February 2022 in continuation of the publication of this Annual Report 2021, this presentation, and wr Novo Nordisk, may contain forward- looking statements. Words such as ‘believe’, ‘expect, ‘may’, ‘will’, ‘p words and terms of similar meaning in connection with any discussion of future operating or financial include, but are not limited to: • Statements of targets, plans, objectives or goals for future operations, including those related to product approvals as well as cooperation in relation thereto, • Statements containing projections of or targets for revenues, costs, income (or loss), earnings pe measures, • Statements regarding future economic performance, future actions and outcome of contingencie • Statements regarding the assumptions underlying or relating to such statements. These statements are based on current plans, estimates and projections. By their very nature, forward Nordisk cautions that a number of important factors, including those described in this presentation, co statements. Factors that may affect future results include, but are not limited to, global as well as local political and failure of projects related to research and/or development, unplanned loss of patents, interruptions o which Novo Nordisk relies, product recalls, unexpected contract breaches or terminations, governmen competing products, reliance on information technology including the risk of cybersecurity breeches, and legal proceedings and investigations, changes in governmental laws and related interpretation th testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marke growth in costs and expenses, failure to recruit and retain the right employees, failure to maintain a cu domestic or international crises, civil unrest, war or other conflict. For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk’s results or t overview of risk factors in ‘Risk management’ of this Annual Report 2021. Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revi result of new information, future events, or otherwise. Important drug information Victoza ® and Ozempic ® are approved for the management of type 2 diabetes only Saxenda ® and Wegovy ® are approved for the treatment of obesity only
Share
Download PDF file
